DOK4: A Potential Drug Target and Biomarker (G55715)

Target Name: DOK4

NCBI ID: G55715

DOK4

DOK4: A Potential Drug Target and Biomarker

Dukes disease is a type of breast cancer that affects the inner lining of the breast, and it is one of the most common causes of breast cancer in the United States. The disease is characterized by the formation of a non-cancerous (benign) tissue called a dermal ovarian neoplasm, which typically develops on the surface of the ovary. However, when this neoplasm grows to the point where it interrupts the normal flow of blood to the ovary, it can cause symptoms such as pain, swelling, and abnormal cell growth.

DOK4 is a variant of the DOK1 gene, which encodes a protein known as CDKN2A. CDKN2A is a tumor suppressor gene that plays a role in regulating cell growth and division. Mutations in the CDKN2A gene have been linked to the development of various types of cancer, including breast cancer.

One of the key features of DOK4 is its ability to interact with several different drugs that are commonly used to treat breast cancer. For example, some studies have shown that inhibiting the activity of CDKN2A using drugs such as tamoxifen or raloxifene can lead to a regression of existing breast tumors. This suggests that targeting DOK4 may be a promising strategy for the treatment of breast cancer.

In addition to its potential as a drug target, DOK4 has also been shown to be a potential biomarker for breast cancer. The DOK4 gene has been shown to be expressed in a variety of breast tissue samples, including breast milk, tissue samples from primary breast cancers, and metastatic breast cancers. This suggests that DOK4 could be used as a diagnostic biomarker for breast cancer, particularly in cases where there is a high risk of recurrence.

Another potential application of DOK4 is its role in the development of cancer stem cells. Cancer stem cells are cells that have the ability to continuously divide and promote the growth of cancer. The DOK4 gene has been shown to be involved in the development and maintenance of cancer stem cells.

In conclusion, DOK4 is a variant of the DOK1 gene that has been associated with the development of various types of cancer, including breast cancer. The ability of DOK4 to interact with drugs commonly used to treat breast cancer and its potential as a biomarker make it an attractive target for further research. Further studies are needed to fully understand the role of DOK4 in the development and treatment of breast cancer.

Protein Name: Docking Protein 4

Functions: DOK proteins are enzymatically inert adaptor or scaffolding proteins. They provide a docking platform for the assembly of multimolecular signaling complexes. DOK4 functions in RET-mediated neurite outgrowth and plays a positive role in activation of the MAP kinase pathway (By similarity). Putative link with downstream effectors of RET in neuronal differentiation. May be involved in the regulation of the immune response induced by T-cells

The "DOK4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DOK4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets